TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
TAMPA, Fla., May 15, 2025 /PRNewswire/ – TuHURA Biosciences, Inc. (NASDAQ:HURA), a Phase 3 immune-oncology company, today announced its financial results for the first quarter ended March 31, 2025, and provided a corporate update. The company, which focuses on developing novel technologies to overcome resistance to cancer immunotherapy, reported an impressive start to 2025, continuing to execute its corporate strategy.
Key Developments:
Phase 3 Trial Initiation: TuHURA anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma (MCC) in the second quarter of 2025. This trial will be conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
Phase 1b/2a Trial: The company has initiated a Phase 1b/2a trial of IFx-Hu2.0 as adjunctive therapy with pembrolizumab in first-line Merkel cell carcinoma of unknown primary origin (MCCUP).
Acquisition of Kineta, Inc.: TuHURA is targeting to close the acquisition of Kineta, Inc. in Q2 2025. Following the acquisition, the company plans to initiate a Phase 2 trial of Kineta’s VISTA inhibiting monoclonal antibody (mAb) in NPM1-mutated acute myeloid leukemia (AML) in Q3 2025.
Conference Presentation:
TuHURA Biosciences, Inc. will present at the 3rd Annual H.C. Wainwright BioConnect Conference on May 20, 2025. James A. Bianco, M.D., President and Chief Executive Officer, will provide a company overview, highlighting the IFx-Hu2.0 Phase 3 program and the first-in-class bi-specific immune modulating Antibody drug, or peptide conjugates (ADCs, APCs) targeting Myeloid Derived Suppressor Cells (MDSCs). Additionally, the presentation will cover Kineta Inc’s VISTA inhibiting monoclonal antibody program.
Management will also be available for one-on-one in-person meetings with qualified members of the investor community. A live webcast of the fireside chat will be accessible on the Events page of the Investors section of TuHURA’s website (tuhurabio.com).
Company Overview:
TuHURA Biosciences, Inc. is listed on the Nasdaq stock exchange with a market capitalization of $170,350,000 USD. The company’s close price as of May 12, 2025, was $4.1 USD. Over the past year, the stock has seen a 52-week high of $14.595 on May 29, 2024, and a 52-week low of $1.8 on March 9, 2025. TuHURA operates in the Health Care sector, specifically within the Biotechnology industry.